CYP2D亚家族基因及其进化机制研究进展

doi:10.16088/j.issn.1001-6600.2020122201

摘要/Abstract

摘要： CYP2D酶在药物代谢及有毒物质的解毒过程中起重要作用,而认识和了解CYP2D亚家族基因的适应性进化有助于理解CYP2D酶对有毒物质的作用机制。研究表明,CYP2D亚家族基因在进化过程中具有谱系特异性扩张现象。此外,基因复制、基因转换以及选择压力对基因的进化具有一定的影响,但对不同谱系产生的影响程度不同。本文从CYP2D亚家族基因的结构、功能及其进化机制等方面进行综述,以期为理解CYP2D亚家族基因的适应性进化提供理论依据。

关键词: 细胞色素P450, CYP2D基因, 基因复制, 基因转换, 选择压力

Abstract: CYP2D enzyme plays an important role in drug metabolism and the detoxification of toxic substances. Knowing and understanding the adaptive evolution of CYP2D subfamily genes helps to understand the mechanism of CYP2D enzymes on toxic substances. Research has shown that CYP2D subfamily genes have lineage-specific expansion in the evolutionary process. In addition, gene duplication, gene conversion, and selective pressure had a certain influence on the evolution of genes, but the effect varied with different lineages. In this paper, the structure, function and evolutionary mechanism of CYP2D subfamily genes were reviewed, in order to provide a theoretical basis for understanding the adaptive evolution of CYP2D subfamily genes.

Key words: cytochrome P450, CYP2D genes, gene duplication, gene conversion, selective pressure

中图分类号:

梁秋芳, 董小燕, 冯平. CYP2D亚家族基因及其进化机制研究进展[J]. 广西师范大学学报（自然科学版）, 2021, 39(5): 58-63.

LIANG Qiufang, DONG Xiaoyan, FENG Ping. Advanced in CYP2D Subfamily Genes and Evolutionary Mechanisms[J]. Journal of Guangxi Normal University(Natural Science Edition), 2021, 39(5): 58-63.

参考文献

[1] FINNIGAN J D, YOUNG C, COOK D J, et al. Cytochromes P450 (P450s): A review of the class system with a focus on prokaryotic P450s[J]. Advances in Protein Chemistry and Structural Biology, 2020, 122: 289-320. DOI:10.1016/bs.apcsb.2020.06.005.
[2] SEZUTSU H, LE GOFF G, FEYEREISEN R. Origins of P450 diversity[J]. Philosophical Transactions of the Royal Society Series B: Biological Sciences, 2013, 368(1612): 20120428. DOI:10.1098/rstb.2012.0428.
[3] GUENGERICH F P. Intersection of the roles of cytochrome P450 enzymes with xenobiotic and endogenous substrates: Relevance to toxicity and drug interactions[J]. Chemical Research in Toxicology, 2017, 30(1): 2-12. DOI:10.1021/acs.chemrestox.6b00226.
[4] UEHARA S, UNO Y, HAGIHIRA Y, et al. Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan[J]. Xenobiotica: the Fate of Foreign Compounds in Biological Systems, 2015, 45(9): 766-772. DOI:10.3109/00498254.2015.1019595.
[5] KITANOVIC S, ORR T J, SPALINK D, et al. Role of cytochrome P450 2B sequence variation and gene copy number in facilitating dietary specialization in mammalian herbivores[J]. Molecular Ecology, 2018, 27(3): 723-736. DOI:10.1111/mec.14480.
[6] MALENKE J R, MAGNANOU E, THOMAS K, et al. Cytochrome P450 2B diversity and dietary novelty in the herbivorous, desert woodrat (Neotoma lepida)[J]. PLoS ONE, 2012, 7(8): e41510. DOI:10.1371/journal.pone.0041510.
[7] NEBERT D W, ADESNIK M, COON M J, et al. The P450 gene superfamily: recommended nomenclature[J]. DNA, 1987, 6(1): 1-11. DOI:10.1089/dna.1987.6.1.
[8] CHANEY M E, PIONTKIVSKA H, TOSI A J. Retained duplications and deletions of CYP2C genes among primates[J]. Molecular Phylogenetics and Evolution, 2018, 125: 204-212. DOI:10.1016/j.ympev.2018.03.037.
[9] KONSTANDI M, JOHNSON E O, LANG M A. Consequences of psychophysiological stress on cytochrome P450-catalyzed drug metabolism[J]. Neuroscience and Biobehavioral Reviews, 2014, 45: 149-167. DOI:10.1016/j.neubiorev.2014.05.011.
[10] GOTOH O. Evolution of cytochrome P450 genes from the viewpoint of genome informatics[J]. Biological and Pharmaceutical Bulletin, 2012, 35(6): 812-817. DOI:10.1248/bpb.35.812.
[11] NEBERT D W, RUSSELL D W. Clinical importance of the cytochromes P450[J]. The Lancet, 2002, 360(9340): 1155-1162. DOI:10.1016/S0140-6736(02)11203-7.
[12] CHANEY M E, ROMINE M G, PIONTKIVSKA H, et al. Diversifying selection detected in only a minority of xenobiotic-metabolizing CYP1-3 genes among primate species[J]. Xenobiotica: the Fate of Foreign Compounds in Biological Systems, 2020, 50(12): 1406-1412. DOI:10.1080/00498254.2020.1785580.
[13] KIRISCHIAN N, McARTHUR A G, JESUTHASAN C, et al. Phylogenetic and functional analysis of the vertebrate cytochrome P450 2 family[J]. Journal of Molecular Evolution, 2011, 72(1): 56-71. DOI:10.1007/s00239-010-9402-7.
[14] McMILLAN D M, EL-SHERBENI A A, RICHARDS J, et al. Centrally administered CYP2D inhibitors increase oral tramadol analgesia in rats[J]. Brain Research Bulletin, 2020, 164: 400-406. DOI:10.1016/j.brainresbull.2020.09.001.
[15] 董天崴, 王爽, 杨军, 等. CYP2D6基因多态性与药物基因组学研究的进展[J]. 心血管康复医学杂志, 2014, 23(3): 343-346. DOI:10.3969/j.issn.1008-0074.2014.03.35.
[16] 冯平. CYP2D亚家族基因在脊椎动物中的研究进展[J]. 生物学通报, 2018, 53(2): 6-8. DOI:10.3969/j.issn.0006-3193.2018.02.003.
[17] FENG P, LIU Z J. Complex gene expansion of the CYP2D gene subfamily[J]. Ecology and Evolution, 2018, 8(22): 11022-11030. DOI:10.1002/ece3.4568.
[18] YASUKOCHI Y, SATTA Y. Evolution of the CYP2D gene cluster in humans and four non-human primates[J]. Genes & Genetic Systems, 2011, 86(2): 109-116. DOI:10.1266/ggs.86.109.
[19] WATANABE K P, KAWAI Y K, IKENAKA Y, et al. Avian cytochrome P450 (CYP) 1-3 family genes: isoforms, evolutionary relationships, and mRNA expression in chicken liver[J]. PLoS ONE, 2013, 8(9): e75689. DOI:10.1371/journal.pone.0075689.
[20] MARTIGNONI M, GROOTHUIS G M M, DE KANTER R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction[J]. Expert Opinion on Drug Metabolism & Toxicology, 2006, 2(6): 875-894. DOI:10.1517/17425255.2.6.875.
[21] KAWAI Y K, ITOU K, YOSHINO T, et al. Hepatic transcriptional profile and tissue distribution of cytochrome P450 1-3 genes in the red-crowned crane Grus japonensis[J]. Comparative Biochemistry and Physiology Part C: Toxicology and Pharmacology, 2020, 228: 108643. DOI:10.1016/j.cbpc.2019.108643.
[22] GOPISANKAR M G. CYP2D6 pharmacogenomics[J]. Egyptian Journal of Medical Human Genetics, 2017, 18(4): 309-313. DOI:10.1016/j.ejmhg.2017.03.001.
[23] HE Z X, CHEN X W, YANG Y X, et al. A comparison of non-human primate cytochrome P450 2D members and the implication in drug discovery[J]. Current Drug Metabolism, 2016, 17(6): 520-527. DOI:10.2174/138 9200217666160219114241.
[24] YASUKOCHI Y, SATTA Y. Molecular evolution of the CYP2D subfamily in primates: purifying selection on substrate recognition sites without the frequent or long-tract gene conversion[J]. Genome Biology and Evolution, 2015, 7(4): 1053-1067. DOI:10.1093/gbe/evv056.
[25] ALMEIDA D, MALDONADO E, KHAN I, et al. Whole-genome identification, phylogeny, and evolution of the cytochrome P450 family 2 (CYP2) subfamilies in birds[J]. Genome Biology and Evolution, 2016, 8(4): 1115-1131. DOI:10.1093/gbe/evw041.
[26] LYNCH M, CONERY J S. The evolutionary fate and consequences of duplicate genes[J]. Science, 2000, 290(5494): 1151-1155. DOI:10.1126/science.290.5494.1151.
[27] DANIELSON P B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans[J]. Current Drug Metabolism, 2002, 3(6): 561-597. DOI:10.2174/1389200023337054.
[28] GONZALEZ F J, NEBERT D W. Evolution of the P450 gene superfamily: animal-plant “warfare”, molecular drive and human genetic differences in drug oxidation[J]. Trends in Genetics, 1990, 6(6): 182-186. DOI:10.1016/0168-9525(90)90174-5.
[29] THOMAS J H. Rapid birth-death evolution specific to xenobiotic cytochrome P450 genes in vertebrates[J]. PLoS Genetics, 2007, 3(5): e67. DOI:10.1371/journal.pgen.0030067.
[30] TEUFEL A I, JOHNSON M M, LAURENT J M, et al. The many nuanced evolutionary consequences of duplicated genes[J]. Molecular Biology and Evolution, 2019, 36(2): 304-314. DOI:10.1093/molbev/msy210.
[31] FEYEREISEN R. Arthropod CYPomes illustrate the tempo and mode in P450 evolution[J]. Biochimica et Biophysica Acta (BBA): Proteins and Proteomics, 2011, 1814(1): 19-28. DOI:10.1016/j.bbapap.2010.06.012.
[32] WANG X S, LI J, DONG G C, et al. The endogenous substrates of brain CYP2D[J]. European Journal of Pharmacology, 2014, 724: 211-218. DOI:10.1016/j.ejphar.2013.12.025.
[33] TAYLOR C, CROSBY I, YIP V, et al. A review of the important role of CYP2D6 in pharmacogenomics[J]. Genes, 2020, 11(11): 1295. DOI:10.3390/genes11111295.
[34] CAI H, JIANG J, YANG Q, et al. Functional characterization of a first avian cytochrome P450 of the CYP2D subfamily (CYP2D49)[J]. PLoS ONE, 2012, 7(6): e38395. DOI:10.1371/journal.pone.0038395.
[35] TESHIMA K M, INNAN H. The effect of gene conversion on the divergence between duplicated genes[J]. Genetics, 2004, 166(3): 1553-1560. DOI:10.1534/genetics.166.3.1553.
[36] MATSUNAGA E, UMENO M, GONZALEZ F J. The rat P450 IID subfamily: complete sequences of four closely linked genes and evidence that gene conversions maintained sequence homogeneity at the heme-binding region of the cytochrome P450 active site[J]. Journal of Molecular Evolution, 1990, 30(2): 155-169. DOI:10.1007/BF02099942.
[37] MASIMIREMBWA C, PERSSON I, BERTILSSON L, et al. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity[J]. British Journal of Clinical Pharmacology, 1996, 42(6): 713-719. DOI:10.1046/j.1365-2125.1996.00489.x.
[38] BRATTSTEN L B. Enzymic adaptations in leaf-feeding insects to host-plant allelochemicals[J]. Journal of Chemical Ecology, 1988, 14(10): 1919-1939. DOI:10.1007/bf01013486.
[39] INGELMAN-SUNDBERG M. The human genome project and novel aspects of cytochrome P450 research[J]. Toxicology and Applied Pharmacology, 2005, 207(2 sup): 52-56. DOI:10.1016/j.taap.2005.01.030.
[40] WILSON D J, CONSORTIUM C. GenomegaMap: within-species genome-wide d_N/d_S estimation from over 10,000 genomes[J]. Molecular Biology and Evolution, 2020, 37(8): 2450-2460. DOI:10.1093/molbev/msaa069.
[41] SPIELMAN S J, WILKE C O. The relationship between d_N/d_S and scaled selection coefficients[J]. Molecular Biology and Evolution, 2015, 32(4): 1097-1108. DOI:10.1093/molbev/msv003.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed